SCHEMBL14066735

SCHEMBL14066735

Cc1ccccc1-c1c(C)c(C(=O)Nc2ccc(S(C)(=O)=O)c(Cl)c2)cn1CCO

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.58
SMO Q99835 2/20 0.39
USP28 Q96RU2 3/20 0.38
DHODH Q02127 1/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
CA12 O43570 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
LMNA P02545 2/20 0.37
ALDH1A1 P00352 2/20 0.37
APAF1 O14727 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12296563 0.89 NR3C2 (0.75) NR3C2CA12CA2CA9LMNA
SCHEMBL1381973 0.85 NR3C2 (0.54) NR3C2USP28CNR1CNR2CA12
SCHEMBL1383401 0.85 NR3C2 (0.78) NR3C2SMOUSP28HPGDMAOB
SCHEMBL2443971 0.81 NR3C2 (0.75) NR3C2SMOUSP28KMT2AMEN1
SCHEMBL1380286 0.81 NR3C2 (0.69) NR3C2CA12CA2CA9LMNA
SCHEMBL23275830 0.79 NR3C2 (0.77) NR3C2
SCHEMBL29410842 0.79 NR3C2 (0.77) NR3C2
SCHEMBL29379459 0.79 NR3C2 (0.77) NR3C2
SCHEMBL14066733 0.79 NR3C2 (0.68) NR3C2SMOCNR1CNR2MAOB
SCHEMBL20068314 0.78 NR3C2 (0.57) NR3C2KMT2AMEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 NR3C2 119/4885SMO 2751/4885USP28 3824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.